TriangleNCT01587703 · OUTCOME
Tmax for GSK525762-Part 1 QD
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Hours
- Interval / dispersion
- Full Range
- Time frame
- pre-dose,0.25,0.5,1,2,4,8,12,24 and 48 hours post-dose at Week1 Day1 and Week 3 Day 4
What was measured
Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK525762.
Analysis population: PK Parameter Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)
Groups in this outcome
Part 1: GSK525762 2 mg QD
Participants were administered once daily oral dose of 2 mg GSK525762.
Part 1: GSK525762 4 mg QD
Participants were administered once daily oral dose of 4 mg GSK525762.
Part 1: GSK525762 8 mg QD
Participants were administered once daily oral dose of 8 mg GSK525762.
Part 1: GSK525762 16 mg QD
Participants were administered once daily oral dose of 16 mg GSK525762.
Part 1: GSK525762 30 mg QD
Participants were administered once daily oral dose of 30 mg GSK525762.
Part 1: GSK525762 60 mg QD
Participants were administered once daily oral dose of 60 mg GSK525762.
Part 1: GSK525762 80 mg QD
Participants were administered once daily oral dose of 80 mg GSK525762.
Part 1: GSK525762 100 mg QD
Participants were administered once daily oral dose of 100 mg GSK525762.
| Group | Source count |
|---|---|
| Part 1: GSK525762 2 mg QD | 3 |
| Part 1: GSK525762 4 mg QD | 4 |
| Part 1: GSK525762 8 mg QD | 1 |
| Part 1: GSK525762 16 mg QD | 3 |
| Part 1: GSK525762 30 mg QD | 4 |
| Part 1: GSK525762 60 mg QD | 9 |
| Part 1: GSK525762 80 mg QD | 32 |
| Part 1: GSK525762 100 mg QD | 9 |
Reported measurements
Week1;n=3,4,1,3,4,9,32,9
| Group | Source count |
|---|---|
| Part 1: GSK525762 2 mg QD | 3 |
| Part 1: GSK525762 4 mg QD | 4 |
| Part 1: GSK525762 8 mg QD | 1 |
| Part 1: GSK525762 16 mg QD | 3 |
| Part 1: GSK525762 30 mg QD | 4 |
| Part 1: GSK525762 60 mg QD | 9 |
| Part 1: GSK525762 80 mg QD | 32 |
| Part 1: GSK525762 100 mg QD | 9 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1: GSK525762 2 mg QD | 0.5833 | Not reported | 0.500 | 0.633 | Not reported |
| Part 1: GSK525762 4 mg QD | 1.2250 | Not reported | 0.500 | 2.000 | Not reported |
| Part 1: GSK525762 8 mg QD | 1.1000 | Not reported | 1.100 | 1.100 | Not reported |
| Part 1: GSK525762 16 mg QD | 2.0167 | Not reported | 0.333 | 3.967 | Not reported |
| Part 1: GSK525762 30 mg QD | 2.0083 | Not reported | 0.967 | 2.233 | Not reported |
| Part 1: GSK525762 60 mg QD | 1.0000 | Not reported | 0.517 | 4.000 | Not reported |
| Part 1: GSK525762 80 mg QD | 1.0000 | Not reported | 0.250 | 4.000 | Not reported |
| Part 1: GSK525762 100 mg QD | 1.0000 | Not reported | 0.667 | 3.950 | Not reported |
Week3;n=1,2,1,3,4,6,16,6
| Group | Source count |
|---|---|
| Part 1: GSK525762 2 mg QD | 1 |
| Part 1: GSK525762 4 mg QD | 2 |
| Part 1: GSK525762 8 mg QD | 1 |
| Part 1: GSK525762 16 mg QD | 3 |
| Part 1: GSK525762 30 mg QD | 4 |
| Part 1: GSK525762 60 mg QD | 6 |
| Part 1: GSK525762 80 mg QD | 16 |
| Part 1: GSK525762 100 mg QD | 6 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1: GSK525762 2 mg QD | 1.0000 | Not reported | 1.000 | 1.000 | Not reported |
| Part 1: GSK525762 4 mg QD | 2.5083 | Not reported | 1.017 | 4.000 | Not reported |
| Part 1: GSK525762 8 mg QD | 0.5000 | Not reported | 0.500 | 0.500 | Not reported |
| Part 1: GSK525762 16 mg QD | 1.0500 | Not reported | 0.767 | 4.000 | Not reported |
| Part 1: GSK525762 30 mg QD | 0.9000 | Not reported | 0.317 | 4.000 | Not reported |
| Part 1: GSK525762 60 mg QD | 1.0583 | Not reported | 0.500 | 2.033 | Not reported |
| Part 1: GSK525762 80 mg QD | 0.5667 | Not reported | 0.300 | 4.017 | Not reported |
| Part 1: GSK525762 100 mg QD | 1.5000 | Not reported | 0.500 | 2.000 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 0.500
- upper Limit
- 0.633
- value
- 0.5833
- group Id
- OG001
- lower Limit
- 0.500
- upper Limit
- 2.000
- value
- 1.2250
- group Id
- OG002
- lower Limit
- 1.100
- upper Limit
- 1.100
- value
- 1.1000
- group Id
- OG003
- lower Limit
- 0.333
- upper Limit
- 3.967
- value
- 2.0167
- group Id
- OG004
- lower Limit
- 0.967
- upper Limit
- 2.233
- value
- 2.0083
- group Id
- OG005
- lower Limit
- 0.517
- upper Limit
- 4.000
- value
- 1.0000
- group Id
- OG006
- lower Limit
- 0.250
- upper Limit
- 4.000
- value
- 1.0000
- group Id
- OG007
- lower Limit
- 0.667
- upper Limit
- 3.950
- value
- 1.0000
- denoms
- counts
- group Id
- OG000
- value
- 3
- group Id
- OG001
- value
- 4
- group Id
- OG002
- value
- 1
- group Id
- OG003
- value
- 3
- group Id
- OG004
- value
- 4
- group Id
- OG005
- value
- 9
- group Id
- OG006
- value
- 32
- group Id
- OG007
- value
- 9
- units
- Participants
- title
- Week1;n=3,4,1,3,4,9,32,9
- categories
- measurements
- group Id
- OG000
- lower Limit
- 1.000
- upper Limit
- 1.000
- value
- 1.0000
- group Id
- OG001
- lower Limit
- 1.017
- upper Limit
- 4.000
- value
- 2.5083
- group Id
- OG002
- lower Limit
- 0.500
- upper Limit
- 0.500
- value
- 0.5000
- group Id
- OG003
- lower Limit
- 0.767
- upper Limit
- 4.000
- value
- 1.0500
- group Id
- OG004
- lower Limit
- 0.317
- upper Limit
- 4.000
- value
- 0.9000
- group Id
- OG005
- lower Limit
- 0.500
- upper Limit
- 2.033
- value
- 1.0583
- group Id
- OG006
- lower Limit
- 0.300
- upper Limit
- 4.017
- value
- 0.5667
- group Id
- OG007
- lower Limit
- 0.500
- upper Limit
- 2.000
- value
- 1.5000
- denoms
- counts
- group Id
- OG000
- value
- 1
- group Id
- OG001
- value
- 2
- group Id
- OG002
- value
- 1
- group Id
- OG003
- value
- 3
- group Id
- OG004
- value
- 4
- group Id
- OG005
- value
- 6
- group Id
- OG006
- value
- 16
- group Id
- OG007
- value
- 6
- units
- Participants
- title
- Week3;n=1,2,1,3,4,6,16,6
- denoms
- counts
- group Id
- OG000
- value
- 3
- group Id
- OG001
- value
- 4
- group Id
- OG002
- value
- 1
- group Id
- OG003
- value
- 3
- group Id
- OG004
- value
- 4
- group Id
- OG005
- value
- 9
- group Id
- OG006
- value
- 32
- group Id
- OG007
- value
- 9
- units
- Participants
- description
- Blood samples were collected at the indicated time points for pharmacokinetic analysis of GSK525762.
- dispersion Type
- Full Range
- groups
- description
- Participants were administered once daily oral dose of 2 mg GSK525762.
- id
- OG000
- title
- Part 1: GSK525762 2 mg QD
- description
- Participants were administered once daily oral dose of 4 mg GSK525762.
- id
- OG001
- title
- Part 1: GSK525762 4 mg QD
- description
- Participants were administered once daily oral dose of 8 mg GSK525762.
- id
- OG002
- title
- Part 1: GSK525762 8 mg QD
- description
- Participants were administered once daily oral dose of 16 mg GSK525762.
- id
- OG003
- title
- Part 1: GSK525762 16 mg QD
- description
- Participants were administered once daily oral dose of 30 mg GSK525762.
- id
- OG004
- title
- Part 1: GSK525762 30 mg QD
- description
- Participants were administered once daily oral dose of 60 mg GSK525762.
- id
- OG005
- title
- Part 1: GSK525762 60 mg QD
- description
- Participants were administered once daily oral dose of 80 mg GSK525762.
- id
- OG006
- title
- Part 1: GSK525762 80 mg QD
- description
- Participants were administered once daily oral dose of 100 mg GSK525762.
- id
- OG007
- title
- Part 1: GSK525762 100 mg QD
- param Type
- MEDIAN
- population Description
- PK Parameter Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)
- reporting Status
- POSTED
- time Frame
- pre-dose,0.25,0.5,1,2,4,8,12,24 and 48 hours post-dose at Week1 Day1 and Week 3 Day 4
- title
- Tmax for GSK525762-Part 1 QD
- type
- SECONDARY
- unit Of Measure
- Hours
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice